Brand Tirzepatide
Zepbound
Zepbound · Eli Lilly
What is Zepbound?
Zepbound (tirzepatide 2.5mg-15mg) is the weight management formulation of tirzepatide. Clinical trials (SURMOUNT-1) showed average weight loss of ~22% at the 15mg dose over 72 weeks — among the highest in clinical trials for any obesity medication.
FDA Approval Status
FDA-approved November 2023 for chronic weight management. Most recently approved GLP-1-class weight loss medication.
Dosing Schedule
2.5mg once weekly, increasing by 2.5mg every 4 weeks up to 15mg maximum.
Eligibility Criteria
BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition.
Common Side Effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach pain
- Fatigue
This is not a complete list. Discuss risks with your healthcare provider.
Compare Medications
Quick Facts
TypeBrand Tirzepatide
ManufacturerEli Lilly
RouteSubcutaneous injection
FrequencyOnce weekly
CompoundedBrand only